Adicet Bio, Inc. (ACET)

• $1.40

  $1.51

  $1.48
  

  5.41%

  Downside

  Day's Volatility :6.98%

  Upside

  1.66%

  
• $1.05

  $3.77

  $1.48
  

  29.05%

  Downside

  52 Weeks Volatility :72.15%

  Upside

  60.74%

  

Returns

What analysts predicted

Upside of 508.11%

• Orbimed Advisors, LLC

  13.89%

• TANG CAPITAL MANAGEMENT LLC

  9.97%

• RA Capital Management, LLC

  9.15%

• Goldman Sachs Group Inc

  5.20%

• Morgan Stanley - Brokerage Accounts

  4.94%

• Millennium Management LLC

  4.40%

adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v